Studies have demonstrated that local angiotensin II (AngII) generation is enhanced in repairing kidney and angiotensin converting enzyme (ACE) inhibition or AT1 receptor blockade attenuates renal fibrosis. The localization of ACE and AngII receptors and their relationship to collagen synthesis in the injured kidney, however, remains uncertain. Using a rat model of renal injury with subsequent fibrosis created by chronic elevations in circulating aldosterone (ALDO), we examined the distribution and binding density of ACE and AngII receptors in repairing kidneys, as well as their anatomic relationship to transforming growth factor (TGF)-beta 1 mRNA, type I collagen mRNA, collagen accumulation and myofibroblasts (myoFb). Two groups of animals (nϭ7/group) were studied: 1) normal rats served as controls; and 2) uninephrectomized rats received ALDO (0.75mg/hr sc) and 1% NaCl in drinking water for 6 weeks. Compared to controls, in ALDO-treated rats we found: 1) significantly (PϽ0.01) increased blood pressure and reduced plasma renin activity and increased plasma creatinine; 2) diffuse fibrosis in both renal cortex and medulla; 3) abundant myoFb at these sites of fibrosis, 4) significantly increased (PϽ0.01) binding density of ACE and AngII receptors (60% AT1: 40% AT2) at sites of fibrosis; and 5) markedly increased (PϽ0.01) expression of TGF-beta 1 and type I collagen mRNAs at these same sites. Thus, in this rat model of renal repair, enhanced expression of ACE, AngII receptors and TGF-beta 1 are associated with renal fibrosis. AngII generated at sites of repair appears to have autocrine/paracrine functions in regulating renal fibrous tissue formation alone or through its stimulation of TGF-beta 1 synthesis. Introduction: The goal of gene therapy for hypertension is to produce safe, prolonged reductions of high blood pressure with a single administration of a transgene. We have develeloped gene therapy using adenoassociated virus (AAV) antisense (AS) as a vector because it is safe, stable and effective. To test systemic injection in an adult hypertensive model, this study uses double transgenic (dt) mice, with human renin (hR) and human transgenes. In these mice, plasma Ang II levels are elevated and blood pressure increased (~140-160 mmHg), compared to controls (~100 mmHg). Methods: Therefore, dt mice with established baseline BP of Ͼ140-160 mmHg (nϭ5) were systemically injected (100 l) with a single dose of 4x10 10 infectious particles of rAAV-AT 1 R-AS. The rAAV contained a CMV promoter and neo 1 reporter gene. Control (nϭ5) received the rAAV vector without AS. Blood pressure recordings by the tailcuff method were made once per week for up to 6 months. Results: One week after injection, BP decreased by 35-50 mmHg (pϽ0.001, compared to baseline). The normalized blood pressure persisted for the full length of the study. Individual mice were sacrificed at 14-28 weeks and tissues taken for detection of rAAV-AT 1 -R-AS. At both time periods, the AS-AT 1 R transgene was present in lung, kidney, liver, heart, adrenal gland and fat. The rAAV was not detected in the brain.
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Introduction: The goal of gene therapy for hypertension is to produce safe, prolonged reductions of high blood pressure with a single administration of a transgene. We have develeloped gene therapy using adenoassociated virus (AAV) antisense (AS) as a vector because it is safe, stable and effective. To test systemic injection in an adult hypertensive model, this study uses double transgenic (dt) mice, with human renin (hR) and human transgenes. In these mice, plasma Ang II levels are elevated and blood pressure increased (~140-160 mmHg), compared to controls (~100 mmHg). Methods: Therefore, dt mice with established baseline BP of Ͼ140-160 mmHg (nϭ5) were systemically injected (100 l) with a single dose of 4x10 10 infectious particles of rAAV-AT 1 R-AS. The rAAV contained a CMV promoter and neo 1 reporter gene. Control (nϭ5) received the rAAV vector without AS. Blood pressure recordings by the tailcuff method were made once per week for up to 6 months. Results: One week after injection, BP decreased by 35-50 mmHg (pϽ0.001, compared to baseline). The normalized blood pressure persisted for the full length of the study. Individual mice were sacrificed at 14-28 weeks and tissues taken for detection of rAAV-AT 1 -R-AS. At both time periods, the AS-AT 1 R transgene was present in lung, kidney, liver, heart, adrenal gland and fat. The rAAV was not detected in the brain.
Renal arterioles (nϭ6) showed a reduction (50%) contractile response to increasing log doses of Ang II, compared to controls (nϭ6) (pϽ0.01). Autoradiography of AT 1 -R showed a reduction in receptors in the rAAT-AT 1 R-AS treated group only. Conclusion: The results demonstrated that a single systemic delivery of rAAV-AT 1 R-AS in adult, hypertensive mice produces a profound decrease in blood pressure for at least 6 months. The prolonged effect is due to the continuous expression of the AT 1 R AS transgene inhibiting AT 1 receptors. The results encourage further development of the rAAV with engineering to make AS transgene expression tissue-specific and switchable on or off for safety. Excessive circulating angiotensin II (Ang II) and reduced nitric oxide (NO) are independently associated with end organ damage. However, low dose infusions of Ang II that only increase plasma Ang II levels 2-fold, cause no detectable end organ damage (Hu et al J Hyper 16: 1285 , 1998 . To determine possible interactions between the two systems, we coinfused low dose Ang II and L-NAME in chronically catheterized Sprague-Dawley rats.
After 5 days saline infusion, L-NAME (10 g/kg/min) was infused for 20 days. After 6 days of L-NAME, Ang II (10ng/kg/min) was coinfused for 14 days (LA, 16 rats). Two other groups of rats were infused with L-NAME (L, 8 rats), or saline (C, 5 rats) alone.
Blood pressure and heart rate were monitored continuously. Plasma renin (PRC) was measured daily. Plasma cardiac troponin T (cTnT) and urinary albumin (UA) were measured as indices of cardiac and renal damage, respectively. At the end of the study, hearts and kidneys were assessed histologically.
cTnT rose and then fell sharply 1 to 4 days after the start of Ang II, and then remained elevated. cTnT was always undetectable in L or C rats. UA began to rise after 4-5 days Ang II infusion and continued to rise thereafter. L-NAME done did not increase UA. Unlike L rats, LA rats had extensive cardiac and renal perivascular fibrosis, glomerular damage, and an increase in the overall cardiac collagen volume. Renal parenchymal damage was increased in both LA and L rats, but was much greater in the LA group.
Taken together, these observations show that there is greatly increased renal and cardiac damage when Ang II and L-NAME are infused together over two weeks at doses that, when infused alone, produce relatively little injury. Thus, Ang II may cause greater end organ damage in a setting of reduced NO bioavailability. In vitro studies have shown that telmisartan is an insurmountable angiotensin II AT-1 receptor antagonist. In this study we have investigated the molecular basis of this insurmountable antagonism. The association and dissociation kinetics of telmisartan to angiotensin AT-1 receptors were
